- Home
- EPM vs CRBP Comparison
EPM vs CRBP Comparison
Compare EPM & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EPM | CRBP |
|---|---|---|
| Founded | 2003 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 158.2M | 147.4M |
| IPO Year | 1996 | 2014 |
Fundamental Metrics
Financial Performance| Metric | EPM | CRBP |
|---|---|---|
| Price | $4.24 | $10.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $4.83 | ★ $45.60 |
| AVG Volume (30 Days) | ★ 350.9K | 195.7K |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | ★ 11.35% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $43,229,621.00 | $4,822,272.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | $84.60 | ★ N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $3.19 | $5.90 |
| 52 Week High | $5.70 | $20.56 |
Technical Indicators
Market Signals| Indicator | EPM | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 40.01 | 57.73 |
| Support Level | $3.19 | $9.86 |
| Resistance Level | $4.27 | $10.21 |
| Average True Range (ATR) | 0.15 | 0.69 |
| MACD | -0.05 | 0.02 |
| Stochastic Oscillator | 8.53 | 72.57 |
Price Performance
Historical ComparisonAbout EPM Evolution Petroleum Corporation Inc.
Evolution Petroleum Corp is an independent energy company focused on owning and investing in onshore oil and natural gas properties across the United States. Its portfolio includes non-operated interests in various production fields such as CO2 enhanced oil recovery in Louisiana, secondary recovery production in Wyoming, and shale gas reservoirs in Texas and North Dakota. The company generates revenue from the production and sale of oil and natural gas, leveraging specialized technologies to extend reservoir life and enhance recoveries.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.